| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
NRx Pharmaceuticals Inc (NASDAQ: NRXP)
NRXP Technical Analysis
5
| As on 9th Jun 2023 NRXP SHARE Price closed @ 0.51 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.76 & Strong Sell for SHORT-TERM with Stoploss of 3.72 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NRXPSHARE Price
| Open | 0.55 | Change | Price | % |
| High | 0.55 | 1 Day | -0.02 | -3.77 |
| Low | 0.51 | 1 Week | -0.19 | -27.14 |
| Close | 0.51 | 1 Month | -0.10 | -16.39 |
| Volume | 443688 | 1 Year | -5.08 | -90.88 |
| 52 Week High 5.59 | 52 Week Low 0.51 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| NRXP Daily Charts |
NRXP Intraday Charts |
Whats New @ Bazaartrend |
NRXP Free Analysis |
|
|
NRXP Important Levels Intraday
| RESISTANCE | 0.59 |
| RESISTANCE | 0.56 |
| RESISTANCE | 0.55 |
| RESISTANCE | 0.53 |
| SUPPORT | 0.49 |
| SUPPORT | 0.47 |
| SUPPORT | 0.46 |
| SUPPORT | 0.43 |
NRXP Forecast April 2024
| 4th UP Forecast | 5.75 |
| 3rd UP Forecast | 4.07 |
| 2nd UP Forecast | 3.03 |
| 1st UP Forecast | 1.99 |
| 1st DOWN Forecast | -0.97 |
| 2nd DOWN Forecast | -2.01 |
| 3rd DOWN Forecast | -3.05 |
| 4th DOWN Forecast | -4.73 |
NRXP Weekly Forecast
| 4th UP Forecast | 2.49 |
| 3rd UP Forecast | 1.86 |
| 2nd UP Forecast | 1.46 |
| 1st UP Forecast | 1.07 |
| 1st DOWN Forecast | -0.05 |
| 2nd DOWN Forecast | -0.44 |
| 3rd DOWN Forecast | -0.84 |
| 4th DOWN Forecast | -1.47 |
NRXP Forecast2024
| 4th UP Forecast | 10.47 |
| 3rd UP Forecast | 7.28 |
| 2nd UP Forecast | 5.3 |
| 1st UP Forecast | 3.33 |
| 1st DOWN Forecast | -2.31 |
| 2nd DOWN Forecast | -4.28 |
| 3rd DOWN Forecast | -6.26 |
| 4th DOWN Forecast | -9.45 |
NRx Pharmaceuticals Inc ( NASDAQ USA Symbol : NRXP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NRXP Business Profile
NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware. Address: 1201 Orange Street, Wilmington, DE, United States, 19801
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service